ClassID:

97042

C07K14/7055 - CPC Classification

Classification description:

Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants; Integrin superfamily Integrin beta1-subunit-containing molecules, e.g. CD29, CD49

Recent Application in this class:
#1
20260000775
2026-01-01

a4ß1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF

#2
20250144213
2025-05-08

CIRCULAR RNA AND USE THEREOF

#3
20240383964
2024-11-21

De Novo Designed alpha(5) beta(1) Integrin selective minibinders

#4
20240270822
2024-08-15

PLATELET TARGETED TREATMENT

#5
20230226109
2023-07-20

METHOD FOR DIFFERENTIATING INNATE LYMPHOID CELLS FOR IMMUNOTHERAPY

#6
20230201272
2023-06-29

CELL-BASED THERAPIES AND USES THEREOF

#7
20220356226
2022-11-10

COMPOUNDS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

#8
20220160760
2022-05-26

RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY

#9
20210283189
2021-09-16

METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS

#10
20210100837
2021-04-08

TREATMENT OF FIBROSIS WITH GENETICALLY-ENGINEERED MACROPHAGES

#11
20190270791
2019-09-05

PLATELET TARGETED TREATMENT

#12
20180369410
2018-12-27

Dendrimer-exosome hybrid nanoparticles as a delivery platform

#13
20180105572
2018-04-19

Cyclic monomer and dimer peptides having integrin antagonist activity

#14
20180094042
2018-04-05

Lung cancer diagnosis marker, antibody and application thereof

#15
20180009874
2018-01-11

Platelet targeted treatment

#16
20150344541
2015-12-03

Platelet targeted treatment

#17
20140341892
2014-11-20

ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES

#18
20130323311
2013-12-05

Collagen-targeted nanoparticles

#19
20130164216
2013-06-27

Bladder cancer tumor marker, antibody and use thereof

#20
20120114708
2012-05-10

INTEGRIN HETERODIMER AND AN ALPHA SUBUNIT THEREOF

#21
20110189095
2011-08-04

CRKL TARGETING PEPTIDES

#22
20110135635
2011-06-09

Anti-alpha2 integrin antibodies and their uses

#23
20110098444
2011-04-28

Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis

#24
20110033923
2011-02-10

Marker for stem cells and its use

#25
20100222424
2010-09-02

Method of Screening Drug with the Use of 67 kDa Laminin Receptor and Drug Obtained Thereby

#26
20100168025
2010-07-01

Treatment of stroke using domain V of perlecan

#27
20100160228
2010-06-24

METHOD FOR INHIBITING OR STIMULATING ANGIOGENESIS IN AN INDIVIDUAL

#28
20100150931
2010-06-17

NOVEL RECEPTOR FOR CD40L AND USES THEREOF

#29
20090185979
2009-07-23

Integrin Heterodimer and an Alpha Subunit Thereof

#30
20090155223
2009-06-18

CELL-BASED COMPOSITIONS AND METHODS FOR TREATING CONDITIONS OF THE NERVOUS SYSTEM

#31
20090054344
2009-02-26

ANTI-ANGIOGENIC PROTEINS AND FRAGMENTS AND METHODS OF USE THEREOF

#32
20080153756
2008-06-26

Novel Peptides and Methods for the Treatment of Inflammatory Disorders

#33
20080051346
2008-02-28

Compounds and methods for modulating cell-adhesion mediated drug resistance

#34
20070128190
2007-06-07

Anti-α2 integrin antibodies and their uses

#35
20070116673
2007-05-24

Method for activating T cell protein tyrosine phosphatase for therapeutic applications

#36
20070021321
2007-01-25

Method of screening drug with the use of 67 kDa laminin receptor and drug obtained thereby

#37
20050221327
2005-10-06

Marker for stem cells and its use

#38
20050113305
2005-05-26

Compounds and methods for modulating cell-adhesion mediated drug resistance

#39
20050069985
2005-03-31

Assay methods and amelioration of muscular dystrophy symptoms